Spero Therapeutics (SPRO) Q2 FY26 earnings call

Spero Therapeutics completed a transformative quarter, securing FDA approval for Utebzi, which enabled a strategic pivot to immunology. The company in-licensed SP001, a promising CD40 ligand antibody, and bolstered its financial position with a significant non-dilutive financing, extending its cash runway. This strategic realignment, supported by new leadership, positions Spero to advance its lead immunology asset into clinical development, focusing on high unmet medical needs.